ArticleFrontiers in endocrinology2026
Association between aldosterone and the risk of cardiovascular disease in hypertensive patients: a cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Whether plasma aldosterone concentration (PAC) is associated with incident cardiovascular disease (CVD) remains unclear in hypertensive patients, particularly after excluding those with primary aldosteronism. This study evaluates the association between PAC and incident CVD. Methods: This study included hypertensive patients admitted to the hypertension center between January 1, 2014, and December 31, 2017, who had PAC measurements. Incident events encompassed both cardiac events and stroke. Cox proportional hazards models were used to evaluate the association between PAC and the outcome. Results: A total of 8653 hypertensive patients were included in this study. During a median follow-up of 5.2 years, 737 cases of incident CVD occurred. The incidence of the outcome increased with higher quartiles of PAC. Individuals in the highest quartile of PAC had a 51% increased risk of CVD (HR 1.51, 95% CI 1.23-1.86) compared to those in the lowest quartile. The overall results remained stable and consistent in the stratification and sensitivity analyses. Conclusions: Higher PAC was associated with increased risk of CVD in hypertensive patients, irrespective of concomitant primary aldosteronism. These findings suggest that PAC might be a target for early prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.